Novartis (NVS) Stock Plunges 12% as Del-Desiran Trial Flops in Brutal Week
Key Takeaways Novartis plunged more than 12% on Tuesday, experiencing its steepest decline since March 2020. The del-desiran candidate failed to meet its primary endpoint in the Phase III HAR






